Recent News

If you are aware of any news items that would be of interest to the RQA membership, please contact the RQA office.

• MHRA public consultation on its plans to apply analytical quality by design (AQbD) principles to its Pharmacopoeia

  12th June 2019

  The MHRA opened a three-month public consultation (until August 31, 2019) on its plans to apply analytical quality by design (AQbD) principles to its pharmacopoeia.

  Read More+

• MHRA - GCP Serious Breaches - the 2018 Edition

  3rd June 2019

  MHRA's GCP Serious Breaches metrics and examples have been released.

  Read More+

• GOOD STORAGE AND DISTRIBUTION PRACTICES

  29th May 2019

  WHO Document for Consultation GOOD STORAGE AND DISTRIBUTION PRACTICES

  Read More+

• MHRA STEM Minutes

  29th May 2019

  Minutes and presentations now available.

  Read More+

• Brexit: EU supports pharmaceutical Companies

  6th March 2019

  Medicinal products imported into the EU must undergo batch testing within the EU and the European Economic Area (EEA)*. Once the United Kingdom (UK) leaves the EU (Brexit), pharmaceutical manufacturers who have previously carried out batch testing in the UK must relocate their batch testing operations to the EU/EEA in order to import their products.

  Read More+

• Brexit: Handling PV Data from the UK

  6th March 2019

  The European Medicines Agency (EMA) has updated the agency's Brexit-related guidance documents. This guidance is supporting pharmaceutical companies to prepare for the United Kingdom's (UK) withdrawal from the European Union (EU). Now the 'Questions and Answers' document has been updated (Rev 04, published on 1st February 2019). The new Q&As address the situation when the United Kingdom becomes a third country on 30th March 2019 without a withdrawal agreement (and hence without a transition period).

  Read More+

• Brexit-related guidance for companies

  25th February 2019

  The European Medicines Agency (EMA) and the European Commission are providing guidance to help pharmaceutical companies responsible for both human and veterinary medicines prepare for the United Kingdom's (UK) withdrawal from the European Union (EU), a process known as 'Brexit'.

  Read More+

• MHRA Pharmacovigilance Inspection Metrics

  6th February 2019

  The MHRA GPvP inspectorate recently published their latest inspection metrics for the period from April 2017 to March 2018.

  Read More+

• EMA - Change of Address

  5th February 2019

  The EMA London office will close on the 1st March 2019 and re-open on the 4th March in Amsterdam....

  Read More+

• EMA Relocation Updates

  23rd January 2019

  The European Medicines Agency (EMA) will physically relocate to the Netherlands in early March 2019. The Dutch authorities have already officially handed over the temporary building, the Spark building in Amsterdam Sloterdijk, to EMA’s Executive Director Guido Rasi on 9 January 2019 and EMA is now preparing for its physical move.

  Read More+

• MHRA Guidance in the event of a no-deal Brexit

  3rd January 2019

  MHRA Guidance on the regulation of medicines, medical devices and clinical trials if there’s no Brexit deal....

  Read More+